Green Valley Investors LLC lessened its stake in shares of Celgene Co. (NASDAQ:CELG) by 7.2% during the third quarter, HoldingsChannel reports. The firm owned 1,128,271 shares of the biopharmaceutical company’s stock after selling 87,810 shares during the period. Celgene accounts for about 4.5% of Green Valley Investors LLC’s portfolio, making the stock its 5th biggest position. Green Valley Investors LLC’s holdings in Celgene were worth $100,969,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in Celgene during the 2nd quarter worth about $281,000. Sumitomo Mitsui Trust Holdings Inc. increased its position in Celgene by 11.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,648,481 shares of the biopharmaceutical company’s stock worth $210,342,000 after purchasing an additional 268,597 shares in the last quarter. Psagot Investment House Ltd. increased its position in Celgene by 241.6% during the 2nd quarter. Psagot Investment House Ltd. now owns 284,910 shares of the biopharmaceutical company’s stock worth $22,628,000 after purchasing an additional 201,502 shares in the last quarter. SeaTown Holdings Pte. Ltd. purchased a new stake in Celgene during the 2nd quarter worth about $4,765,000. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in Celgene by 2,010.1% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,089 shares of the biopharmaceutical company’s stock worth $166,000 after purchasing an additional 1,990 shares in the last quarter. 72.87% of the stock is currently owned by institutional investors.
A number of analysts have issued reports on CELG shares. BidaskClub raised Celgene from a “hold” rating to a “buy” rating in a research note on Thursday, August 16th. Cann reissued a “buy” rating on shares of Celgene in a research note on Monday. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a research note on Thursday, October 11th. Mizuho set a $117.00 price target on Celgene and gave the stock a “buy” rating in a research note on Tuesday, October 30th. Finally, UBS Group set a $94.00 price target on Celgene and gave the stock a “buy” rating in a research note on Saturday, October 27th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. Celgene presently has a consensus rating of “Buy” and an average price target of $116.99.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.02 by $0.27. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. Sell-side analysts expect that Celgene Co. will post 7.45 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Green Valley Investors LLC Cuts Stake in Celgene Co. (CELG)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.com-unik.info/2018/12/04/green-valley-investors-llc-cuts-stake-in-celgene-co-celg.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: What is the float in trading stocks?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.